Page 1

November 9 , 2021 CLEARPOINT NEURO ClearPoint Neuro Reports Third Quarter 2021 Results Record Revenue Achieved ; Company Reaffirms 2021 Revenue Forecast SOLANA BEACH , Calif . , Nov. 09 , 2021 ( GLOBE NEWSWIRE ) . ClearPoint Neuro , Inc. ( Nasdaq : CLPT ) ( the " Company " ) , a global therapy - enabling platform company providing navigation and delivery to the brain , today announced financial results for its third quarter ended September 30 , 2021 . Third Quarter Highlights • Reported record revenue of $ 4.6 million , a 30 % year - over - year increase ; • Increased biologics and drug delivery revenue to $ 2.1 million , a 39 % year - over - year increase ; • Achieved additional biologics and drug delivery relationships , bringing current count of active partners to approximately 40 ; • Initiated development program for a navigation and delivery system for Brain - Computer Interfaces ; • Supported 227 cases despite the impact of the Delta variant on elective procedures , a 14 % year - over - year increase ; and Launched Patient Education Program to increase awareness around DBS options , including awake MER - guided procedures and MRI - guided procedures under general anesthesia . Business Outlook The Company continues to estimate total case volume support to be in the range of 900 1000 for 2021 ; and The Company continues to estimate revenue to be between $ 16.0 and $ 17.5 million for 2021 . " The ClearPoint Neuro Team continued to execute against our four - pillar growth strategy in the third quarter and celebrated a number of successes along the way , " commented Joe Burnett , President and CEO . " First , we achieved record revenue in both Functional Neurosurgery Navigation and Biologics & Drug Delivery , yielding total revenue of $ 4.6 M which represents year - over - year growth of 30 % growth . These results are in spite of the